Piramal Pharma’s division -- Piramal Critical Care (PCC) has launched new 10mg/10mL (1 mg/mL) concentration of Zinc Sulfate for Injection USP in the U.S. The launch will enable PCC to further expand their existing Zinc Sulfate Injection product line and overall the generic injectables portfolio.

Zinc Sulfate is a trace element indicated in adult and pediatric patients as a source of zinc for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.

This intravenous nutritional injection is available in three strengths: 30mg/10mL (3mg/mL), 25mg/5mL (5mg/mL), and the new 10mg/10mL (1mg/mL) concentration. The 1 mg/mL concentration is recommended for use in pediatric patients, particularly those weighing less than 26 pounds.

The launch of Zinc Sulfate for Injection, USP 10mg/10ml is the latest in a series of recent product launches from Piramal Critical Care in the generic injectables market. In 2023, Piramal Critical Care also announced launches of Pantoprazole Sodium for Injection, USP and Doxycycline for Injection, USP to further complement their wide portfolio of critical care products.

Piramal Pharma provides end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.